SI-BONE Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for SI-BONE in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SI-BONE stock.
View analyst ratings for SI-BONE or view top-rated stocks.

Wall Street analysts have given SI-BONE a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but SI-BONE wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

SI-BONE is scheduled to release its next quarterly earnings announcement on Monday, August 2nd 2021.
View our earnings forecast for SI-BONE.

SI-BONE, Inc. (NASDAQ:SIBN) issued its quarterly earnings data on Sunday, May, 2nd. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.03. The business earned $20.44 million during the quarter, compared to the consensus estimate of $19.08 million. SI-BONE had a negative trailing twelve-month return on equity of 31.92% and a negative net margin of 56.06%.
View SI-BONE's earnings history.

SI-BONE's stock was trading at $15.32 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SIBN stock has increased by 104.9% and is now trading at $31.39.
View which stocks have been most impacted by COVID-19.

SI-BONE updated its FY 2021 earnings guidance on Monday, May, 17th. The company provided EPS guidance of - for the period. The company issued revenue guidance of $92 million-$94 million, compared to the consensus revenue estimate of $93.17 million.

7 brokerages have issued 1 year target prices for SI-BONE's stock. Their forecasts range from $25.00 to $43.00. On average, they expect SI-BONE's stock price to reach $38.63 in the next year. This suggests a possible upside of 23.0% from the stock's current price.
View analysts' price targets for SI-BONE or view top-rated stocks among Wall Street analysts.

10 employees have rated SI-BONE CEO Jeffrey Dunn on Glassdoor.com. Jeffrey Dunn has an approval rating of 41% among SI-BONE's employees. This puts Jeffrey Dunn in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to SI-BONE include Glaukos (GKOS), Cantel Medical (CMD), Merit Medical Systems (MMSI), AtriCure (ATRC), NuVasive (NUVA), Haemonetics (HAE), Axonics (AXNX), Inovio Pharmaceuticals (INO), iRhythm Technologies (IRTC), Luminex (LMNX), Silk Road Medical (SILK), Pulmonx (LUNG), Cardiovascular Systems (CSII), Treace Medical Concepts (TMCI) and Alphatec (ATEC).
View all of SIBN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other SI-BONE investors own include Honeywell International (HON), CVS Health (CVS), The Home Depot (HD), The Procter & Gamble (PG), Raytheon Technologies (RTX), Thermo Fisher Scientific (TMO), Verizon Communications (VZ), Alibaba Group (BABA), Cisco Systems (CSCO) and CSX (CSX).

(SIBN) raised $84 million in an initial public offering (IPO) on Wednesday, October 17th 2018. The company issued 6,000,000 shares at $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch acted as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

SI-BONE trades on the NASDAQ under the ticker symbol "SIBN."

SI-BONE's stock is owned by many different institutional and retail investors. Top institutional shareholders include Gilder Gagnon Howe & Co. LLC (7.53%), BlackRock Inc. (6.85%), Lord Abbett & CO. LLC (5.33%), Orbimed Advisors LLC (3.98%), Loomis Sayles & Co. L P (2.63%) and Brown Advisory Inc. (2.47%). Company insiders that own SI-BONE stock include Anthony J Recupero, Jeffrey W Dunn, John Gordon Freund, Laura Francis, Michael A Pisetsky, Scott A Yerby, Skyline Venture Partners V Lp and W Carlton Reckling.
View institutional ownership trends for SI-BONE.

SIBN stock was sold by a variety of institutional investors in the last quarter, including Royce & Associates LP, Ameriprise Financial Inc., Morgan Stanley, Gilder Gagnon Howe & Co. LLC, Tamarack Advisers LP, Orbimed Advisors LLC, Russell Investments Group Ltd., and Renaissance Technologies LLC. Company insiders that have sold SI-BONE company stock in the last year include Anthony J Recupero, Jeffrey W Dunn, John Gordon Freund, Laura Francis, and Michael A Pisetsky.
View insider buying and selling activity for SI-BONE or view top insider-selling stocks.

SIBN stock was acquired by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Loomis Sayles & Co. L P, Brown Advisory Inc., Principal Financial Group Inc., Principal Financial Group Inc., Summit Partners Public Asset Management LLC, Intrinsic Edge Capital Management LLC, and Amundi Asset Management US Inc..
View insider buying and selling activity for SI-BONE or or view top insider-buying stocks.

Shares of SIBN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SIBN stock can currently be purchased for approximately $31.39.

SI-BONE has a market capitalization of $1.03 billion and generates $73.39 million in revenue each year. The company earns $-43,700,000.00 in net income (profit) each year or ($1.50) on an earnings per share basis.

SI-BONE employs 295 workers across the globe.

The official website for SI-BONE is www.si-bone.com.

SI-BONE is headquartered at 471 EL CAMINO REAL SUITE 101, SANTA CLARA CA, 95050.

SI-BONE's mailing address is 471 EL CAMINO REAL SUITE 101, SANTA CLARA CA, 95050. The company can be reached via phone at 408-207-0700 or via email at [email protected]